Vera Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
VERA$30.61+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Class A Common Stock · Additional Paid-in · Accumulated Other Comprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balances as of December 31, 2022 | 27,800,861 | $28 | $290,216 | $(224) | $(213,112) | $76,908 |
| Issuance of common stock from underwritten follow-on offering, net of offering costs | 16,428,572 | 16 | 107,727 | — | — | 107,743 |
| Issuance of common stock pursuant to exercise of options | 111,927 | — | 781 | — | — | 781 |
| Issuance of common stock upon vesting of restricted stock units | 66,321 | — | — | — | — | — |
| Issuance of common stock pursuant to employee stock purchase plan | 44,480 | — | 275 | — | — | 275 |
| Stock-based compensation | — | — | 11,493 | — | — | 11,493 |
| Unrealized gain on marketable securities | — | — | — | 475 | — | 475 |
| Net loss | — | — | — | — | (95,990) | (95,990) |
| Balances as of December 31, 2023 | 44,452,161 | $44 | $410,492 | $251 | $(309,102) | $101,685 |
| Issuance of common stock from underwritten follow-on offering, net of offering costs | 17,488,480 | 18 | 593,219 | — | — | 593,237 |
| Issuance of common stock pursuant to exercise of options | 1,486,314 | 2 | 12,866 | — | — | 12,868 |
| Issuance of common stock upon vesting of restricted stock units | 108,409 | — | — | — | — | — |
| Issuance of common stock pursuant to employee stock purchase plan | 28,944 | — | 545 | — | — | 545 |
| Proceeds from short swing settlement | — | — | 37 | — | — | 37 |
| Repurchase of common stock | (4,450) | — | (13) | — | — | (13) |
| Stock-based compensation | — | — | 20,802 | — | — | 20,802 |
| Unrealized gain on marketable securities | — | — | — | 142 | — | 142 |
| Net loss | — | — | — | — | (152,148) | (152,148) |
| Balances as of December 31, 2024 | 63,559,858 | $64 | $1,037,948 | $393 | $(461,250) | $577,155 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.